Soc Nephrologie :: groupes de travail

anti-angiogéniques (4)

accueil / société / groupes de travail /

Références

1. Miles D. Management of toxicity in patients receiving therapy with bevacizumab. Eur J Cancer 2008;(suppl 6):29-39.
2. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
3. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews. 2004;4:581-11.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl J Med 2007;356:115-24.
6. Escudier B, Eisen T, Stadler WM, et al. Sorafénib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med 2007;356:125-34.
7. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafénib improves survival in advanced hepatocellular carcinoma: Results of a Phase III randomized placebo-controlled trial (SHARP study). J Clin Oncol 2007;25:LBA1.
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
9. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 ;357:2666-76.
10. Rini BI, Rathmell WK. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res. 2007;13:741s-746s.
11. Remontet L, Estève J, Bouvier AM, et al. Cancer incidence and mortality in France over the period 1978-2000 Rev Epidemiol Sante Publique, 2003, 51:3-30.
12. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27.
13. Ferrara N, Berber HN, LeCouter J. The biology of VEGF and its receptors. Nature Medecine. 2003;9:669-76.
14. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998;94:715-25.
15. Houck KA, Ferrara N, Winer J, et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991;5:1806-14.
16. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991;266:11947-54.
17. Keyt BA, Berleau LT, Nguyen HV, et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem. 1996:271:7788-95.
18. Le Tourneau C, Faivre S, Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat Rev. 2008;34:37-48.
19. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
20. Muller YA, Chen Y, Christinger HW, et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure. 1998;6:1153-67.
21. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65:671-80.
22. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. J Clin Oncol 2008;26:2013–9.
23. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
24. Schmiegel WH, Reinacher-Schick A, Freier W, Dietrich G, Arnold D, Kanzler S, et al. Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group. J Clin Oncol 2007;25(Suppl 18S):4034a
25. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
26. George DJ, Michaelson MD, Rosenberg JE, et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers. Proc Am Soc Clin Oncol 2007;25:243s.
27. http://ctep.cancer.gov/reporting/ctc.html
28. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med 2008;358:95-7.
29. Glusker P, Larry Recht L, Lane L. Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab. N Engl J Med 2006;354:980-1.
30. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003;107:1359-1365
31. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008;19:927-34.
32. Veronese, M.L., A. Mosenkis, K.T. Flaherty, M. Gallagher, J.P. Stevenson, R.R. Townsend, and P.J. O'Dwyer. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24:1363-1369.
33. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-93.
34. DH Johnson, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191.
35. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007; 49:e23-29.
36. Izzedine H., Brocheriou I, Rixe O, Deray. Interstitial nephritis in a patient taking sorafénib. Nephrol Dial Transplant 2007;22:241.
37. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF Inhibition and Renal Thrombotic Microangiopathy. N Engl J Med 2008;358:1129-36.
38. Frangié C, Lefaucheur C, Medioni J, et al. Renal thrombotic microangiopathy caused by anti-VEGFantibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007;8:177-78.
39. Izzedine H, Brocheriou I, Deray G, et al. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant. 2007;22:1481-2.
40. Ayllon J, Janus N, Launay-Vacher V,et al. Proc Am Soc Clin Oncol 2008 abstract – No 16001 Vol 26.
41. Sugimoto H., Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278:12605-12608.
42. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658.
43. Strevel EL, Ing DJ, Siu LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007;25:3362-71
44. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al.. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011
45. http://www.has-sante.fr/portail/display.jsp?id=c_272459.
46. http://afssaps.sante.fr/htm/5/liste_tensio_1.htm.
47. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
48. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
49. ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. ESH-ESC Task Force on the Management of Arterial Hypertension. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. J Hypertens 2007;25:1751–1762.
50. Wolter P, Dumez H, Schoffski P. Sunitinib and hypothyroidism. N Engl J Med 2007;356:1580.
51. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 2007;18:1117.
52. van Heeckeren WJ. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol. 2007;25:2993-5.
53. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
54. Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother 2006;40:2278-2279.
55. Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 2007; 3:287-293.
56. Barakat RK, Singh N, Lal R, Verani RR, Finkel KW, Foringer JR. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma. Ann Pharmacother 2007;41:707-710.
57. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al.safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
58. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, et al. Phase II placebo-controlled randomized discontinuation trial of sorafénib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
59. Sun S, Schiller JH. Angiogenesis inhibitors in the treatment of lung cancer. Crit Rev Oncol Hematol 2007;62:93-104.
60. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474-5483.
61. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafénib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9:117-23.

Légendes des figures

Fig.1 : Biopsie rénale sous anti VEGF

Microangiopathie thrombotique glomérulaire montrant des cellules endothéliales turgescentes (endothéliose) et de nombreux double-contour des parois avec espace clair. Zones de mésangiolyse. Trichrome de Masson x 400 (photographie fournie par le Pr Dominique Nochy).

Fig.2 : Marquage des podocytes avec l'anticorps monoclonal anti-VEGF.

Marquage des corps des podocytes normaux. Biopsie d'une MAT des anti-VEGF. X 1000 (photographie fournie par le Pr Dominique Nochy).

Fig.3 : Evaluation de la pression artérielle avant traitement par anti-angiogénique

Fig.4 : Evaluation de la fonction rénale et de la protéinurie avant administration d'un traitement anti-angiogénique

Fig.5 : Prise en charge de la pression artérielle au cours du suivi

Fig.6 : Associations thérapeutiques recommandées au cours de l’HTA

Fig.7 : Prise en charge de l’atteinte rénale au cours du suivi

soc nephrol 1998-2012

webmestre - à propos - qui sommes-nous - about us